{{Drugbox
| Watchedfields = changed
| verifiedrevid = 447568158
| IUPAC_name = (8''S'',13''S'',14''S'',17''R'')-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,14,15,16-octahydrocyclopenta[''a'']phenanthren-3-one
| image = Gestrinone.svg
| width = 250

<!--Clinical data-->
| tradename = Dimetriose, Dimetrose, Nemestran, others
| Drugs.com = {{drugs.com|international|gestrinone}}
| pregnancy_category = X
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]], [[vaginal administration|vaginal]]<ref name="ThomasRock2012" />

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = [[Liver]]
| excretion = [[Urine]], [[feces]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 16320-04-0
| ATC_prefix = G03
| ATC_suffix = XA02
| PubChem = 27812
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 25877
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1421533RCM
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04317

<!--Chemical data-->
| C=21 | H=24 | O=2 
| molecular_weight = 308.41 g/mol
| SMILES = O=C4\C=C3/C(=C2/C=C\[C@]1([C@@H](CC[C@]1(C#C)O)[C@@H]2CC3)CC)CC4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,13,18-19,23H,3,5-8,10,12H2,1H3/t18-,19+,20+,21+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BJJXHLWLUDYTGC-ANULTFPQSA-N
| synonyms = <small>Ethylnorgestrienone; A-46745; R2323; R-2323; RU-2323; 17α-Ethynyl-18-methyl-δ<sup>9,11</sup>-19-nortestosterone; 17α-Ethynyl-18-methylestra-4,9,11-trien-17β-ol-3-one; 13β-Ethyl-18,19-dinor-17α-pregna-4,9,11-trien-20-yn-17β-ol-3-one</small>
}}

'''Gestrinone''' (brand names '''Dimetriose''', '''Dimetrose''', '''Nemestran''') is a [[synthetic compound|synthetic]] [[steroid]] that is used in the treatment of [[endometriosis]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA595|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=595–}}</ref><ref name="Index Nominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA488|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=488, 1288}}</ref><ref name="MortonHall1999">{{cite book|author1=Dr. Ian Morton|author2=I.K. Morton|author3=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=mqaOMOtk61IC&pg=PA132|date=31 October 1999|publisher=Springer Science & Business Media|isbn=978-0-7514-0499-9|pages=132–}}</ref> It has mixed [[progestogen]]ic and [[antiprogestogen]]ic, weak [[androgen]]ic, [[antigonadotropic]], and functional [[antiestrogen]] activity.<ref name="Berek2007"/><ref name="ThomasRock2012">{{cite book|author1=Eric J. Thomas|author2=John Rock|title=Modern Approaches to Endometriosis|url=https://books.google.com/books?id=AFP1CAAAQBAJ&pg=PA228|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-3864-2|pages=228,234}}</ref><ref name="FRCOG2015">{{cite book|author=Howard J.A. Carp, MB, BS, FRCOG|title=Progestogens in Obstetrics and Gynecology|url=https://books.google.com/books?id=Ik8SCAAAQBAJ&pg=PA141|date=9 April 2015|publisher=Springer|isbn=978-3-319-14385-9|pages=141–}}</ref><ref name="BromhamBooker1995">{{cite journal | last1 = Bromham | first1 = D. R. | last2 = Booker | first2 = M. W. | last3 = Rose | first3 = Gillian | last4 = Wardle | first4 = P. G. | last5 = Newton | first5 = J. R. | title = A multicentre comparative study of gestrinone and danazol in the treatment of endometriosis | journal = Journal of Obstetrics and Gynaecology | volume = 15 | issue = 3 | year = 1995 | pages = 188–194 | issn = 0144-3615 | doi = 10.3109/01443619509015498}}</ref> Gestrinone is described as similar in action and effect to [[danazol]], which is also used in the treatment of endometriosis, but is reported to have fewer androgenic [[side effect]]s in comparison.<ref name="ShawLuesley2010">{{cite book|author1=Robert W. Shaw|author2=David Luesley|author3=Ash K. Monga|title=Gynaecology: Expert Consult: Online and Print|url=https://books.google.com/books?id=Ylqqk9-5zUsC&pg=PT2175|date=1 October 2010|publisher=Elsevier Health Sciences|isbn=0-7020-4838-0|pages=2175–}}</ref><ref name="Gupta2011">{{cite book|author=Sadhana Gupta|title=A Comprehensive Textbook of Obstetrics and Gynecology|url=https://books.google.com/books?id=5GiDegG69E0C&pg=PT171|date=14 March 2011|publisher=JP Medical Ltd|isbn=978-93-5025-112-6|pages=171–}}</ref> Because of its [[anabolic]] effects, the use of gestrinone in competition has been banned by the [[International Olympic Committee]].<ref>{{cite web|date=May 2000 |url=http://sport-dc.com/medcom/CANADA-LIST.pdf |title=Helping athletes compete drug-free |format=PDF |pages=34 |publisher=Canadian Centre for Ethics in Sport |accessdate=2006-06-01 |archiveurl=https://web.archive.org/web/20060517045357/http://sport-dc.com/medcom/CANADA-LIST.pdf |archivedate=2006-05-17 |deadurl=yes |df= }}</ref>

==Medical uses==
Gestrinone is approved for and used in the treatment of [[endometriosis]].

===Other uses===
Gestrinone has also been investigated for use as a prospective [[contraceptive]] agent and as a [[Emergency contraception|postcoital contraceptive]].<ref>{{cite web|date=October 2006 |url=http://www.cecinfo.org/files/ecupdate-9610.rtf |title=Emergency Contraception Update |format=RTF |pages=5 |publisher=International Consortium for Emergency Contraception |accessdate=2006-06-01 |archiveurl=https://web.archive.org/web/20060620192932/http://www.cecinfo.org/files/ecupdate-9610.rtf |archivedate=2006-06-20 |deadurl=yes |df= }}</ref> It also has been used to shrink [[uterine fibroid]]s and to reduce [[menorrhagia]].<ref>{{cite journal | last = La Marca | first = A. |author2=Giulini S. |author3=Vito G. |author4=Orvieto R. |author5=Volpe A. |author6=Jasonni V.M. |date=December 2004 | title = Gestrinone in the treatment of uterine leiomyomata: effects on uterine blood supply | journal = Fertility and Sterility | volume = 82 | issue = 6 | pages = 1694–6 | pmid = 15589885 | doi = 10.1016/j.fertnstert.2004.08.004}}<!--| accessdate = 2006-06-01 --></ref><ref>{{cite journal | last = Roy | first = SN. |author2=Bhattacharya S. | year = 2004 | title = Benefits and risks of pharmacological agents used for the treatment of menorrhagia | journal = Drug safety : an international journal of medical toxicology and drug experience | volume = 27 | issue = 2 | pages = 75–90 | pmid = 14717620 | doi=10.2165/00002018-200427020-00001}}<!--| accessdate = 2006-06-01 --></ref>

==Contraindications==
The drug is contraindicated in [[pregnancy]], during [[lactation]], and in patients with severe cardiac, renal or hepatic insufficiency. It is also contraindicated in patients who experienced metabolic and/or vascular disorders during previous estrogen or progestogen therapy, or who are allergic to the medication. The drug is contraindicated in children.

==Side effects==
{{See also|Anabolic steroid#Adverse effects}}

[[Side effect]]s of gestrinone include vaginal spotting, and, in susceptible individuals, signs of increased androgen activity such as acne, oily skin, fluid retention, weight gain, hirsutism, voice change, or hair loss.

==Pharmacology==
The [[mechanism of action]] of gestrinone is complex and multifaceted.<ref name="ThomasRock2012" /><ref name="ShawLuesley2010" /> It shows high [[affinity (pharmacology)|affinity]] for the [[progesterone receptor]] (PR), as well as lower affinity for the [[androgen receptor]] (AR).<ref name="ThomasRock2012" /><ref name="ShawLuesley2010" /> The drug has mixed [[progestogen]]ic and [[antiprogestogen]]ic activity – that is, it is a [[partial agonist]] of the PR or a [[selective progesterone receptor modulator]] (SPRM) – and is a weak [[agonist]] of the AR, or an [[anabolic–androgenic steroid]] (AAS).<ref name="Berek2007" /><ref name="ThomasRock2012" /><ref name="FRCOG2015" /><ref name="BromhamBooker1995" /> Similarly to danazol, gestrinone acts as a weak [[antigonadotropin]] via activation of the PR and AR in the [[pituitary gland]] and suppresses the mid-cycle surge of [[luteinizing hormone]] (LH) and [[follicle-stimulating hormone]] (FSH) during the [[menstrual cycle]] without affecting basal levels of these hormones.<ref name="ThomasRock2012" /><ref name="ShawLuesley2010" /> It also inhibits [[ovarian]] [[steroidogenesis]] and, via activation of the AR in the [[liver]], decreases circulating levels of [[sex hormone-binding globulin]] (SHBG), thereby resulting in increased levels of free [[testosterone]].<ref name="ThomasRock2012" /><ref name="ShawLuesley2010" /><ref name="ArakawaMitsuma1989">{{cite journal|last1=Arakawa|first1=Satoko|last2=Mitsuma|first2=Mizue|last3=Iyo|first3=Masato|last4=Ohkawa|first4=Ryoichi|last5=Kambegawa|first5=Akira|last6=Okinaga|first6=Shoichi|last7=Arai|first7=Kiyoshi|title=Inhibition of Rat Ovarian 3.BETA.-Hydroxysteroid Dehydrogenase (3.BETA.-HSD), 17.ALPHA.-Hydroxylase and 17, 20 Lyase by Progestins and Danazol.|journal=Endocrinologia Japonica|volume=36|issue=3|year=1989|pages=387–394|issn=0013-7219|doi=10.1507/endocrj1954.36.387}}</ref> In addition to the PR and AR, gestrinone has been found to bind to the [[estrogen receptor]] (ER) with relatively "avid" affinity.<ref name="pmid3490730">{{cite journal | vauthors = Tamaya T, Fujimoto J, Watanabe Y, Arahori K, Okada H | title = Gestrinone (R2323) binding to steroid receptors in human uterine endometrial cytosol | journal = Acta Obstet Gynecol Scand | volume = 65 | issue = 5 | pages = 439–41 | year = 1986 | pmid = 3490730 | doi = 10.3109/00016348609157380| url = }}</ref> The drug has functional antiestrogenic activity in the [[endometrium]].<ref name="Berek2007" /><ref name="ThomasRock2012" /><ref name="FRCOG2015" /><ref name="BromhamBooker1995" /> Unlike danazol, gestrinone does not appear to bind to SHBG or [[corticosteroid-binding globulin]] (CBG).<ref name="pmid3490730" />

==Pharmacokinetics==

===Metabolism===
Gestrinone is [[absorption (pharmacokinetics)|well-absorbed]] with [[oral administration]], is [[metabolism|metabolized]] by the [[liver]], and has a [[terminal half-life]] of about 24&nbsp;hours.{{Citation needed|date=August 2017}} It is [[elimination (pharmacology)|eliminated]] in [[urine]] and [[feces]].{{Citation needed|date=August 2017}}

==Chemistry==
{{See also|List of steroidal progestogens|List of androgens/anabolic steroids}}

Gestrinone, also known as '''17α-ethynyl-18-methyl-19-nor-δ<sup>9,11</sup>-testosterone''', as well as '''17α-ethynyl-18-methylestra-4,9,11-trien-17β-ol-3-one''' or as '''13β-ethyl-18,19-dinor-17α-pregna-4,9,11-trien-20-yn-17β-ol-3-one'''), is a [[synthetic compound|synthetic]] [[estrane]] [[steroid]] and a [[chemical derivative|derivative]] of [[testosterone]].<ref name="Elks2014" /><ref name="Index Nominum2000" /> It is more specifically a derivative of [[norethisterone]] (17α-ethynyl-19-nortestosterone) and is a member of the [[gonane]] (18-methylestrane) subgroup of the [[19-nortestosterone]] family of progestins.<ref name="CarrellPeterson2010">{{cite book|author1=Douglas T. Carrell|author2=C. Matthew Peterson|title=Reproductive Endocrinology and Infertility: Integrating Modern Clinical and Laboratory Practice|url=https://books.google.com/books?id=lcBEheiufVcC&pg=PA200|date=23 March 2010|publisher=Springer Science & Business Media|isbn=978-1-4419-1436-1|pages=200–}}</ref><ref name="Berek2007">{{cite book|author=Jonathan S. Berek|title=Berek & Novak's Gynecology|url=https://books.google.com/books?id=P3erI0J8tEQC&pg=PA1167|year=2007|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-6805-4|pages=1167–}}</ref><ref name="BlandIII2009">{{cite book|author1=Kirby I. Bland|author2=Edward M. Copeland III|title=The Breast: Comprehensive Management of Benign and Malignant Diseases|url=https://books.google.com/books?id=1u4x_iGiHNEC&pg=PA93|date=9 September 2009|publisher=Elsevier Health Sciences|isbn=1-4377-1121-9|pages=93–}}</ref><ref name="Lachelin2013">{{cite book|author=Gillian C. L. Lachelin|title=Introduction to Clinical Reproductive Endocrinology|url=https://books.google.com/books?id=RaHpAgAAQBAJ&pg=PA109|date=11 September 2013|publisher=Elsevier Science|isbn=978-1-4831-9380-9|pages=109–}}</ref> Gestrinone is the C18 [[methyl group|methyl]] derivative of [[norgestrienone]] (17α-ethynyl-19-nor-δ<sup>9,11</sup>-testosterone) and the δ<sup>9,11</sup> [[structural analog|analogue]] of [[levonorgestrel]] (17α-ethynyl-18-methyl-19-nortestosterone) and is also known as '''ethylnorgestrienone''' due to the fact that it is the C13β [[ethyl group|ethyl]] variant of norgestrienone.<ref name="BlackwellOlive2012">{{cite book|author1=Richard E. Blackwell|author2=David L. Olive|title=Chronic Pelvic Pain: Evaluation and Management|url=https://books.google.com/books?id=pJwxBQAAQBAJ&pg=PP106|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4612-1752-7|pages=106–}}</ref><ref name="GomelBrill2010">{{cite book|author1=Victor Gomel|author2=Andrew Brill|title=Reconstructive and Reproductive Surgery in Gynecology|url=https://books.google.com/books?id=C4TOBQAAQBAJ&pg=PA90|date=27 September 2010|publisher=CRC Press|isbn=978-1-84184-757-3|pages=90–}}</ref> It is also the C17α [[ethynyl group|ethynyl]] and C18 methyl derivative of the AAS [[trenbolone]].<ref name="ThiemeHemmersbach2009">{{cite book|author1=Detlef Thieme|author2=Peter Hemmersbach|title=Doping in Sports|url=https://books.google.com/books?id=R-hIC-caIn8C&pg=PA160|date=18 December 2009|publisher=Springer Science & Business Media|isbn=978-3-540-79088-4|pages=160–162}}</ref><ref name="Litwack2012">{{cite book|author=Gerald Litwack|title=Biochemical Actions of Hormones|url=https://books.google.com/books?id=tX9GwWPsMbQC&pg=PA321|date=2 December 2012|publisher=Elsevier|isbn=978-0-323-15344-7|pages=321–}}</ref>

The androgenic properties of gestrinone are more exploited in its derivative [[tetrahydrogestrinone]] (THG; 17α-ethyl-18-methyl-δ<sup>9,11</sup>-19-nortestosterone), a [[designer steroid]] which is far more potent as both an AAS and progestogen in comparison.<ref name="DeathMcGrath2004">{{cite journal|last1=Death|first1=Alison K.|last2=McGrath|first2=Kristine C. Y.|last3=Kazlauskas|first3=Rymantas|last4=Handelsman|first4=David J.|title=Tetrahydrogestrinone Is a Potent Androgen and Progestin|journal=The Journal of Clinical Endocrinology & Metabolism|volume=89|issue=5|year=2004|pages=2498–2500|issn=0021-972X|doi=10.1210/jc.2004-0033|pmid=15126583}}</ref> THG was banned by the [[Food and Drug Administration]] (FDA) in 2003.<ref name="Hollinger2007">{{cite book|author=Mannfred A. Hollinger|title=Introduction to Pharmacology, Third Edition|url=https://books.google.com/books?id=qfrLBQAAQBAJ&pg=PA235|date=19 October 2007|publisher=CRC Press|isbn=978-1-4200-4742-4|pages=235–}}</ref>

==History==
Gestrinone was introduced in 1986.<ref name="AcademicPress1988">{{cite book|title=Annual Reports in Medicinal Chemistry|url=https://books.google.com/books?id=Plq6RpLymIcC&pg=PA387|date=1 November 1988|publisher=Academic Press|isbn=978-0-08-058367-9|pages=387–}}</ref>

==Society and culture==

===Generic name===
''Gestrinone'' is the [[generic term|generic name]] of the drug and its {{abbrlink|INN|International Nonproprietary Name}}, {{abbrlink|USAN|United States Adopted Name}}, {{abbrlink|BAN|British Approved Name}}, and {{abbrlink|JAN|Japanese Accepted Name}}.<ref name="Elks2014" /><ref name="Index Nominum2000" /><ref name="Drugs.com">https://www.drugs.com/international/gestrinone.html</ref>

===Brand names===
Gestrinone is or has been marketed under the brand names '''Dimetriose''', '''Dimetrose''', Dinone, Gestrin, and '''Nemestran'''.<ref name="Elks2014" /><ref name="Index Nominum2000" /><ref name="Drugs.com" />

===Availability===
Gestrinone is or has been marketed in [[Europe]], [[Australia]], [[Latin America]], and [[Southeast Asia]],<ref name="Index Nominum2000" /><ref name="Drugs.com" /> though notably not in the [[United States]].<ref name="LedgerSchlaff2014">{{cite book|author1=William Ledger|author2=William D. Schlaff|author3=Thierry G. Vancaillie|title=Chronic Pelvic Pain|url=https://books.google.com/books?id=ON-VBQAAQBAJ&pg=PA57|date=11 December 2014|publisher=Cambridge University Press|isbn=978-1-316-21414-5|pages=57–}}</ref>

==References==
{{Reflist|2}}


{{Androgens and antiandrogens}}
{{Progestogens and antiprogestogens}}
{{Androgen receptor modulators}}
{{Progesterone receptor modulators}}

[[Category:3β-Hydroxysteroid dehydrogenase inhibitors]]
[[Category:Alcohols]]
[[Category:Alkynes]]
[[Category:Androgens and anabolic steroids]]
[[Category:Antiestrogens]]
[[Category:Antigonadotropins]]
[[Category:Antiprogestogens]]
[[Category:CYP17A1 inhibitors]]
[[Category:Estranes]]
[[Category:Ketones]]
[[Category:Progestogens]]
[[Category:World Anti-Doping Agency prohibited substances]]